Assembly Biosciences Reveals Interim Data from P-Ib Study of ABI-4334 to Treat Chronic Hepatitis B
Shots:
- The P-Ib (ABI-4334-102) study assessed safety, PK & antiviral activity of ABI-4334 (150 & 400mg) vs PBO in treatment-naive or off-treatment HBeAg +ve/-ve patients with chronic hepatitis B, across 2 arms with recruitment ongoing for 400mg arm
- Interim data depicted a mean HBV DNA decline of 2.9 log10 IU/mL & HBV RNA decline of 2.5 log10 U/mL in HBeAg-ve subjects on 150mg over 28 days, ABI-4334’s half-life supporting QD dosing & plasma trough concentrations exceeding protein-adjusted EC50 for antiviral activity & cccDNA formation
- Built on this data, 400mg arm is expected to be final with results anticipated in H1’25. Additionally, Gilead holds opt-in rights to further develop & commercialize it when full results are out
Ref: Assembly Biosciences | Image: Assembly Biosciences
Related News:-
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
